MicroRNAs hsa-miR-618 and hsa-miR-297 Might Modulate the Pleiotropic Effects Exerted by Statins in Endothelial Cells Through the Inhibition of ROCK2 Kinase: in-silico Approach

Karla Leal, Kathleen Saavedra, Camilo Rebolledo and Luis A. Salazar*

Center of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco, Chile

Several studies show that statin therapy improves endothelial function by cholesterol-independent mechanisms called “pleiotropic effects.” These are due to the inhibition of the RhoA/ROCK kinase pathway, its inhibition being an attractive atheroprotective treatment. In addition, recent work has shown that microRNAs, posttranscriptional regulators of gene expression, can affect the response of statins and their efficacy. For this reason, the objective of this study was to identify by bioinformatic analysis possible new microRNAs that could modulate the pleiotropic effects exerted by statins through the inhibition of ROCK kinases. A bioinformatic study was performed in which the differential expression of miRNAs in endothelial cells was compared under two conditions: Control and treated with simvastatin at 10 μM for 24 h, using a microarray. Seven miRNAs were differentially expressed, three up and four down. Within the up group, the miRNAs hsa-miR-618 and hsa-miR-297 present as a predicted target to ROCK2 kinase. Also, functional and enriched pathway analysis showed an association with mechanisms associated with atheroprotective effects. This work shows an in-silico approach of how posttranscriptional regulation mediated by miRNAs could modulate the pleiotropic effects exerted by statins on endothelial cells, through the inhibition of ROCK2 kinase and its effects.

Keywords: statins, pleiotropic effects, microRNAs, atheroprotective effects, kinases

INTRODUCTION

Cardiovascular diseases (CVDs) are the leading cause of death worldwide. An estimated 17.9 million people died from CVDs in 2016, representing 31% of all global deaths. Of these deaths, 85% are due to heart attack and ischemic stroke (1). Most CVDs can be prevented by addressing lifestyle-related risk factors: tobacco use, physical inactivity, hypertension, diabetes, and hyperlipidemia (2). The treatment of choice for hypercholesterolemia is the use of statins, which inhibit the enzyme 3-hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase, which limits the biosynthesis of liver cholesterol (3). Experimental and clinical studies suggest that statins may exert...
cardiovascular protective effects by mechanisms independent of cholesterol lowering called “pleiotropic effects” (4, 5). It has been described that the mechanism by which statins produce their pleiotropic effects is through inhibition of the mevalonate pathway. Mevalonate is a precursor not only of cholesterol but also of several other isoprenoids (6). These include farnesylpyrophosphate (FPP) and geranylgerany1pyrophosphate (GGP), which are lipid species needed for posttranslational prenylation of Rho GTPase proteins, which act as biological switches through signal transduction (6, 7). The inhibition of mevalonate synthesis prevents the activation of Rho and the subsequent activation of Rho-associated protein kinase (ROCK) (8, 9). Several studies have reported the importance of the RhoA/ROCK pathway in endothelial function affecting vascular tone, platelet aggregation, smooth-muscle cell proliferation, leukocyte adhesion, production of nitric oxide synthase (eNOS), and bioavailability of nitric oxide (NO). The mechanisms associated with eNOS are of great importance, since the decrease of NO corresponds to one of the first manifestations of atherosclerosis (10, 11). Therefore, inhibition of the RhoA/ROCK pathway by statins influences NO signaling in endothelial cells (12). This has been demonstrated by two mechanisms: stability of eNOS messenger RNA (mRNA) and an increase in its activity through activation of phosphatidylinositol 3-kinase (PI3K)/AKT (13, 14). For this reason, inhibition of the RhoA/ROCK kinase pathway might be an attractive atheroprotective treatment for the development of CVD.

MicroRNAs (miRNAs) are important regulators of gene expression that bind complementary target mRNAs and repress their expression. The miRNAs are small non-coding RNA molecules, evolutionarily conserved. They have approximately 22 nucleotides, and their functions are gene regulation through posttranscriptional mechanisms. The miRNAs are involved in a variety of biological processes (15). Over the past few years, a total of 2,300 miRNAs have been reported in humans and it is estimated that human mRNA information exceeds 25,000 (16, 17). For this reason, current laboratory technologies do not allow to test globally every possible interaction between gene and miRNAs. However, the use of bioinformatics approaches for miRNA target prediction is used as a guide for laboratory validation experiments to more quickly elucidate gene regulation networks (18). The bioinformatics development combined with diverse experiments has allowed them to be used as potential biomarkers for diagnosis, prognosis, and personalized treatment (19).

Several studies in the area of cancer have demonstrated the regulation of transcriptional expression by miRNAs of the ROCK1 and ROCK2 isoforms of the RhoA/ROCK kinase pathway, reporting beneficial effects such as decreased proliferation and migration by modulating the expression of these miRNAs (20, 21). Zambrano et al. (22) showed that treatment with atorvastatin and simvastatin at 10 micromolar (µM) in HepG2 cells for 24 h deregulated the expression of 13 miRNAs by atorvastatin and 2 miRNAs by simvastatin. Other studies also show that atorvastatin can lower miR-221 and miR-222 levels in cell endothelial parents of patients with coronary disease (23). In particular, the effects observed by statins are heterogeneous, appearing to be independent of their chemical composition (lipophilic vs. hydrophilic) (24). It has also been reported that miRNAs would have the ability to influence endothelium atheroprotective effects, such as increasing nitric NO. Cerda et al. (25) described that these miRNAs increase the levels of NO and the expression of eNOS3 in endothelial cells. This background reveals that statin-modulated miRNAs influence their response and effectiveness. For this reason, the objective of this study was to identify by bioinformatic analysis possible new miRNAs that could modulate the pleiotropic effects exerted by statins through the inhibition of ROCK1 and ROCK2 kinases, and also to explore the pathways associated with the atheroprotective capacity of endothelial cells through an in-silico approach. Therefore, a bioinformatics study was performed comparing the differential expression of miRNAs in human umbilical vein endothelial cells (HUVES) under two conditions: control and treated with simvastatin at 10 (µM) for 24 h.

MATERIALS AND METHODS

Identification of Differential Expression miRNAs
The gene expression profile data (GSE126290, file GSE126290_RAW.tar) was downloaded from the NCB1 Gene Expression Omnibus (GEO) database. The dataset contained the miRNA profile of HUVEC cells treated with simvastatin 10 µM and HUVEC cells without treatment as control. The analysis was performed using the Gene Expression Analysis Platform version 0.3.2 (GEAP), which uses R program packages for gene expression data processing and statistical analysis (26–30). In this analysis, the statistical package used was “Linear models and differential expression for microarray data” (Llima), making the comparison between groups considering as criteria the “false discovery rate” (FDR) p-value < 0.05 and logFC > 1 (31). From GEAP software, volcano plot, scatter plot, and heat map of the distances between arrays were generated. For principal component analysis (PCA), Ggfortify (32) and ggbiplot (33) of R Program were used. For the hierarchical clustering heat maps, Morpheus was used.

Gene Ontology and Pathway Enrichment Analysis
To predict the target genes of the prognostic miRNAs, we used the mirDIP 4.1 online software that provides 152 million predictions using 30 different resources and obtained the score of each interaction between miRNAs and the target (34). In addition, gene ontology (GO) and pathway enrichment analyses of Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed with target genes of the differential miRNAs expressed through the ShinyGO v0.61 (35) program, FDR p-value < 0.05.

Target Predictions of Upregulated miRNAs for ROCK1 and ROCK2 Kinases
The upregulated miRNAs were evaluated for their ability to bind to the 3′ UTR of the ROCK1 and/or ROCK2 kinases using three miRNA target predictor softwares to increase specificity
and precision: TargetScan version 7.2, which considered as criteria the type of seed region and the weighted context++ score (WCS) that uses 16 important characteristics for miRNA target recognition (36); miRDB which considered as criteria the location of the seed region in the 3’UTR and the score assigned by the computational algorithm for target prediction, showing that a score above 80 presents a higher probability of union (37); and mirDIP 4.1.

RESULTS
Identification of Differentially Expressed miRNAs Between Simvastatin-Treated 10 μM HUVEC Cells (24 h Treatment) and Control HUVEC Cells
To determine the quality control of our analysis, two PCA plots and a false-color heat map were generated. PCA shows
### TABLE 1 | Differentially expressed miRNAs in HUVEC cells treated with 10 μM simvastatin for 24 h.

| miRNA_ID     | logFC | AveExpr | T     | p value | adj. p val | B      | Expression   |
|--------------|-------|---------|-------|---------|------------|--------|--------------|
| hsa-miR-515-5p | -1.07 | 10.1    | -6.94 | 0.000662 | 0.0471     | 0.255  | Downregulated |
| hsa-miR-18a*  | -1.43 | 9.06    | -7.18 | 0.000559 | 0.0471     | 0.43   | Downregulated |
| hsa-miR-640   | -1.35 | 9.31    | -7.06 | 0.00061  | 0.0471     | 0.34   | Downregulated |
| hsa-miR-618   | 1.72  | 5.82    | 6.81  | 0.00073  | 0.0471     | 0.155  | Upregulated   |
| hsa-miR-363   | 1.64  | 10.7    | 13.4  | 2.2E-05  | 0.0191     | 3.48   | Upregulated   |
| hsa-miR-548h  | -1.19 | 12.9    | -10.9 | 6.43E-05 | 0.0191     | 2.55   | Downregulated |
| hsa-miR-297   | 2.1   | 11.7    | 8.53  | 0.000233 | 0.026      | 1.32   | Upregulated   |

logFC, log2 fold change; AveExpr, average log2 expression; T, moderated t-statistic; p-value, raw p-value; adj. p-value, adjusted p-value; B, log-odds.

The separation of the groups in the two conditions evaluated, simvastatin-treated HUVEC cells, and control (untreated) HUVEC cells (Figure 1A). Along with this, the false heat map indicates the distances between the matrices, calculated between the mean distances between the data (Figure 1B). Subsequently, the differential expression of miRNAs from the GSM126290 database is shown. The criteria used were \( p < 0.05 \) and \( \logFC > 1 \) (Table 1). A total of seven miRNAs were identified as differentially expressed, three miRNAs upregulated and four miRNAs downregulated, between the conditions: 10-μM simvastatin-treated and control cells. This was represented in a hierarchical clustering heat map (Figure 1C). Along with this, the volcano plot showing the dataset and the differentially expressed samples is shown (Figure 1D).

### Functional and Pathway Enrichment Analysis of Differentially Expressed miRNAs

Gene Ontology and Pathway Enrichment analysis were made to explore the biological pathways in which deregulated miRNAs would be implicated. The first step was to determine the target genes for differentially expressed miRNAs, using the mirDIP 4.1 program. This program brings together 30 different resources. A total of 4,756 target genes were found with extremely high score. Later, the 4,756 genes were used for ontological genes and enrichment pathways. Gene Ontology enrichment analysis classified them into three groups, a biological process group, a cellular component group, and a molecular function group, which are shown in Table 2. The biological processes that showed the highest number of genes were regulation of biosynthetic processes (1,055 genes), regulation of macromolecule biosynthetic processes (1,010 genes), and positive regulation of nitrogen compound metabolic processes (819 genes). The cellular components genes are mostly associated with nuclear part (1,060 genes), nucleoplasm (869 genes), and nuclear lumen (976 genes). The most presented molecular functions were transcription regulator activity (543 genes), regulatory region nucleic acid binding (301 genes), and transcription regulatory region DNA binding (299 genes). Pathway enrichment analysis shows miRNAs in cancer, axon guidance, and pathways in cancer, in higher probability, which are shown in Table 3 and Figure 2.

### DISCUSSION

In the present in-silico study, we analyzed data collected from the GEO database (GSE126290) in which the differential expression of miRNAs between two conditions was evaluated: HUVEC cells treated with simvastatin at 10 μM and control cells (without treatment) for 24 h. The bioinformatic analysis on differential expression analysis of miRNAs showed the deregulation of a group of seven miRNAs (hsa-miR-515-5p, hsa-miR-18a*, hsa-miR-640, hsa-miR-618, hsa-miR-363, hsa-miR-548h, and hsa-miR-297) considering as cutoff criteria a logFC > 1 and FDR \( p \)-value < 0.05. Among the group of seven miRNAs, four are downregulated (hsa-miR-515-5p, hsa-miR-18a*, hsa-miR-640, and hsa-miR-548h) and three are upregulated (hsa-miR-618, hsa-miR-297, and hsa-miR-363). Liang et al. (38) performed a differential expression analysis from the same data set presented in this paper. Their results showed that miRNA hsa-miR-652-3p inhibits ISL1, a protein involved in the decrease of NO bioavailability in endothelial cells. However, this miRNA is not upregulated in our analysis. One of these differences is due to their cutoff values considered: \( p \)-value of 0.1 and fold change ± 0.2. This would also establish a difference in the amount of deregulated miRNAs, since they present a total of 167, in relation to our analysis which were 7.

Our work supports previous reports on the effect of statins on the dysregulation of miRNA expression and also proposes the way in which statins can exert pleiotropic effects associated with...
Leal et al. MicroRNAs and Effects of Statins

TABLE 2 | Gene ontology enrichment analysis of differentially expressed miRNAs was divided into three groups: biological processes, cellular components, and molecular functions.

| Functional category                              | E. FDR | N. G. S | N. G. T |
|--------------------------------------------------|--------|--------|--------|
| **BIOLOGICAL PROCESS**                           |        |        |        |
| Nervous system development                       | 4.6E-72| 696    | 2,474  |
| Positive regulation of metabolic process         | 2.4E-60| 911    | 3,789  |
| Positive regulation of macromolecule metabolic process | 2.4E-60| 858    | 3,498  |
| Regulation of biosynthetic process               | 2.2E-56| 1,055  | 4,687  |
| Regulation of macromolecule biosynthetic process | 2.2E-56| 1,010  | 4,426  |
| Positive regulation of nitrogen compound metabolic process | 2.2E-56| 819    | 3,351  |
| Regulation of cellular biosynthetic process      | 6.4E-56| 1,040  | 4,610  |
| Neurogenesis                                      | 7.9E-56| 495    | 1,683  |
| Cell development                                  | 1.8E-55| 604    | 2,230  |
| Regulation of nucleobase-containing compound metabolic process | 6.7E-55| 1,014  | 4,482  |
| **CELLULAR COMPONENT**                           |        |        |        |
| Nuclear part                                      | 1.9E-44| 1,060  | 4,966  |
| Nucleoplasm                                       | 3.1E-44| 869    | 3,861  |
| Nucleus lumen                                     | 1.7E-41| 976    | 4,545  |
| Neuron part                                       | 2.1E-27| 440    | 1,808  |
| Synapse                                           | 5.5E-24| 326    | 1,268  |
| Axon                                              | 7.7E-21| 190    | 639    |
| Neuron projection                                 | 3.5E-20| 333    | 1,371  |
| Plasma membrane bounded cell projection           | 5.8E-19| 481    | 2,214  |
| Cell projection                                   | 8.0E-19| 493    | 2,287  |
| Synapse part                                      | 1.5E-18| 257    | 1,004  |
| **MOLECULAR FUNCTIONS**                          |        |        |        |
| Transcription regulator activity                  | 7.5E-37| 543    | 2,183  |
| Regulatory region nucleic acid binding            | 3.1E-34| 301    | 1,002  |
| Transcription regulatory region DNA binding       | 9.6E-34| 299    | 1,000  |
| Sequence-specific DNA binding                     | 1.1E-33| 338    | 1,189  |
| RNA polymerase II regulatory region DNA binding   | 1.3E-33| 260    | 823    |
| DNA-binding transcription factor activity          | 4.9E-33| 455    | 1,793  |
| RNA polymerase II regulatory region sequence-specific DNA binding | 1.2E-32| 256    | 816    |
| Sequence-specific double-stranded DNA binding     | 1.2E-31| 276    | 920    |
| Transcription regulator region sequence-specific DNA binding | 1.4E-31| 266    | 875    |
| DNA-binding transcription factor activity, RNA polymerase II-specific | 1.4E-31| 427    | 1,673  |

E. FDR, enrichment FDR; N. G. S, number of genes selected; N. G. T, number of genes total.

TABLE 3 | Pathway enrichment analysis of differentially expressed miRNAs.

| Functional category                              | E. FDR | N. G. S | N. G. T |
|--------------------------------------------------|--------|--------|--------|
| **ENRICHMENT PATHWAYS**                          |        |        |        |
| MicroRNAs in cancer                              | 5.5E-13| 62     | 150    |
| Axon guidance                                    | 1.5E-10| 65     | 181    |
| Pathways in cancer                               | 5.4E-09| 134    | 528    |
| MAPK signaling pathway                           | 8.4E-09| 86     | 295    |
| Proteoglycans in cancer                          | 1.6E-08| 64     | 198    |
| Transcriptional misregulation in cancer          | 5.2E-08| 60     | 186    |
| Endocytosis                                      | 8.6E-08| 72     | 244    |
| PI3K-AKT signaling pathway                       | 1.1E-07| 94     | 353    |
| Ubiquitin-mediated proteolysis                    | 1.3E-07| 47     | 135    |
| Signaling pathways regulating pluripotency of stem cells | 1.3E-07| 48     | 139    |

E. FDR, enrichment FDR; N. G. S, number of genes selected; N. G. T, number of genes total.

The miRNA sequence with the 3′UTR region of the target gene (41). However, many of these predictions show false negatives in the experimental validation. One strategy to maximize performance and minimize false results in vitro and in vivo functional experiments is the union of bioinformatics tools for miRNA-target prediction that will allow increasing the specificity and precision of the analysis (42). For this reason, three prediction programs were used together: TargetScan, miRDB, and mirDIP 4.1. All three tools showed that hsa-miR-618 and hsa-miR-297 had ROCK2 as a target. The hsa-miR-618 miRNA shows complementarity in three regions of the 3′UTR of ROCK2. Studies have shown that the more seed bonds it has in the 3′UTR, the stronger the miRNA-induced regulation (43). On average, the change in Log2 was linearly correlated with the number of seed regions, suggesting that the effect of seeds is independent and multiplicative (44). For this reason, we can suggest that hsa-miR-618 would have a greater effect on the 3′UTR.

Considering that many of the pathologies associated with the vasculature are related to morphological changes that can be regulated by the interaction of hemodynamic forces, one of the limitations of our work is that the database used contains data from an in vitro model and not from an in vivo model. Also, in the vasculature there is presence of different cell types that contribute to the physiopathology. An example of this, in the adhesion of leukocytes, is the production of inflammatory cytokines by macrophages, etc. However, many authors agree thatHUVEC is a model of representative study of the vasculature and also it has allowed the study of physiological and pathological effects in isolation as in coculture with leukocytes and smooth-muscle cells (45, 46). For this reason, it is important to consider validating these results in vitro and in vivo models.

ROCK2 is a 160-kDa serine/threonine kinase protein, and its functions are the regulation of smooth-muscle contraction, organization of the actin cytoskeleton and stress fibers, formation of focal adhesions, and retraction of neurons and cellular adhesions (47). Therefore, its function in different cells and how it contributes to different pathologies through mechanisms...
mediated by miRNAs have been studied. Liu et al. \(^{(48)}\) demonstrated that hsa-miR-122 can inhibit the proliferation of prostate carcinoma cells due to the negative regulation of ROCK2 expression. Furthermore, the hsa-mir-185/ROCK2 pathway was shown to have potential to improve therapies in hepatocellular carcinoma, through metastasis inhibition \(^{(49)}\). However, miRNAs hsa-miR-618 and hsa-miR-297 have not been experimentally validated as ROCK2 targets. The hsa-miR-618 has been reported to be unregulated in pathologies as epilepsy \(^{(50)}\) and squamous cells from head and neck carcinomas \(^{(51)}\). The case of hsa-miR-297 has been associated with prostate cancer \(^{(52)}\) and with colorectal carcinoma, specifically with drug resistance \(^{(53)}\).

The set of differentially expressed miRNAs and their gene ontological analysis showed the following biological processes: regulation of biosynthesis processes, regulation of biosynthetic

---

**FIGURE 2** | Network figure showing the relationship between the enriched pathways obtained from the classification from KEGG. The nodes in green correspond to an enriched pathway, and their size is related to a set of larger genes. MAPK signaling, PI3K-Akt signaling pathway, pathways in cancer, and proteoglycans in cancer are connected as they share \( \geq 20\% \) of genes. Figure extracted from ShinyGO v0.61.

**TABLE 4** | Software and metrics used to determine the binding of miRNAs with ROCK2.

| miRNA   | Fold change | Gene target | TargetScan | miRDB | mirDIP 4.1 |
|---------|-------------|-------------|------------|-------|------------|
|         | LogFC       | Expression  |            |       |            |
| hsa-miR-618 | 1.75    | Up          | ROCK2      | 7mer-A1 | −0.15      |
|          |            |             |            | 7mer-m8 | −0.04      |
|          |            |             |            | 8mer   | −0.01      |
| hsa-miR-297 | 2.1      | Up          | ROCK2      | 7mer-m8 | −0.06      |
|          |            |             |            | 7mer-m8 | −0.01      |

S.T, site type; C++S, context score; S.L, seed location; T.S, target score.
macromolecule processes, and positive regulation of nitrogen compound metabolic processes; this last process could be related to the gene’s enrichment involved in the mechanisms associated with the ability of statins to increase the bioavailability of NO, through the inhibition of ROCKs (9). The increased expression of ROCKs reduces the expression of eNOS, and the inhibitors (Y-27632 and fasudil) have been shown to increase eNOS (54). In the case of the statins, the increased expression of eNOS was not due to FPP and LDL-C; it was due to inhibition of GGP involved with RhoA and ROCK signaling (6).

Other biological processes and cellular components highlighted in the analysis are neurogenesis, development of the nervous system, and cellular development. Several studies in animal models of spontaneous intracerebral hemorrhage that have been treated with statins have improved neurological function, reduced cerebral edema effects, increasing angiogenesis, and neurogenesis, and have decreased the infiltration of inflammatory cells. This supports the possible neuroprotective effects of statins (55–57).

Statins may also exert their pleiotropic effects through Kruppel-like factor-2 (KLF2). Statins induced the increase in mRNA expression of KLF2 in endothelial cells, which is necessary for eNOS expression (58). This could be associated with the results of molecular functions obtained like the transcription regulator activity in ontological gene analysis.

Inside the analysis associated with the biological pathways, the following ones might be highlighted: signaling pathways regulating pluripotency of stem cells, axon guidance, PI3K-AKT signaling pathways, and miRNAs in cancer. The signaling pathways regulating pluripotency of stem cells has been associated with the transforming growth factor (TGF-B) superfamily, performing important functions during the differentiation of vascular progenitor cells derived from mouse embryonic stem cells (59). Statins can exert pleiotropic effects by increasing the mobilization of endothelial progenitor cells. Damaged endothelial progenitor cells are associated with impaired endothelial function and reduced NO levels. Studies show that prehypertension and hypertension in patients are related to early senescence of progenitor cells and impaired endothelial function (60). Another route mentioned is the axon guidance, which could represent a key stage in the formation of the neural network. This mechanism has been associated with the Rho GTPase pathway through the reorganization of the cytoskeleton that determines the direction that will guide the growth cone (61). A study conducted on brain slices of oxygen-glucose-deprived cells that were exposed to fasudil (ROCK inhibitor) showed an improvement in neuronal viability (62, 63). These findings could be linked to the neuroprotective effects that statins would have on the neurovascular system. Furthermore, the PI3K-AKT signaling pathway corresponds to one of those affected by ROCK inhibition by statins as mentioned above. ROCK is a negative regulator of AKT, possibly through activation of phosphatase and the homolog of tensin (64). Also, the regulation of AKT is known to influence the expression of eNOS and thus an increase in the bioavailability of NO. This effect has been shown to contribute to a decrease in the proliferation of smooth-muscle cells, a key mechanism in the development of atherosclerosis (65). Studies have revealed that statins modulate miRNAs associated with influence the change from senescent contractile phenotype to proliferative phenotype. This could be associated with the enrichment of the miRNA pathway in cancer (66).

Finally, in-silico analysis has shown that statins might exert pleiotropic effects through the modulation of miRNAs that would inhibit ROCK2 kinase and also generate atheroprotective effects in endothelial cells (Figure 4). Although our work proposes new miRNAs that regulate the RhoA/Rock kinase pathway through an in-silico approach, it is necessary to
Bioinformatic analysis showed that miRNAs modulated by statin treatment could exert the pleiotropic effects. These effects would occur due to the posttranscriptional inhibition of ROCK2 kinase by the miRNAs hsa-miR-618 and hsa-miR-297. ROCK2 kinase expression has been described by two mechanisms: stability of eNOS messenger RNA and increased activity by activation of phosphatidylinositol 3-kinase (PI3K)/AKT. The increased activity and expression of eNOS produce an increase in the bioavailability of NO. This effect of increasing NO affects improvement in neuronal viability, mobilization of stem and progenitor cells, and decreased proliferation of smooth muscle cells.

In this work, we report that simvastatin treatment deregulates the expression of seven miRNAs (hsa-miR-515-5p, hsa-miR-18a*, hsa-miR-640, hsa-miR-618, hsa-miR-363, hsa-miR-548h, and hsa-miR-297) in HUVEC cell culture. In-silico analysis shows that the miRNAs hsa-miR-618 and hsa-miR-297 are upregulated, and the 3’UTR region of ROCK2, an important protein of the RhoA/Rock kinase pathway involved in modulation of pleiotropic effects exerted by statins, is predicted as a potential target for both miRNAs. In addition, functional analysis and enriched pathways revealed an important association with the pleiotropic effects produced by statins and with the inhibition of RhoA/ROCKs. These results open a new way to understand how statins, through the deregulation of the miRNA expression, might cause an atheroprotective effect through the inhibition of ROCK2 kinase.

In summary, our work through the use of bioinformatics tools contributes with new potential candidates that could regulate the pleiotropic effects in response to statin treatment. However, the functional role of hsa-miR-618 and hsa-miR-297 miRNAs and their mediation of pleiotropic effects must be evaluated by validating in vitro and in vivo models.
DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data can be found here: Accession number GSE126290.

AUTHOR CONTRIBUTIONS
KL and CR performed the bioinformatics analysis. KL wrote the manuscript. KS and LS contributed in writing—review and editing. All authors read and approved the final manuscript.

FUNDING

This study was supported by the Chilean National Fund for Scientific and Technological Development (FONDECYT, Grant numbers 1171765 and 3160567) and Dirección de Investigación of the Universidad de La Frontera (Grant numbers DI19-2018 and DI19-0094). KL is the recipient of ANID scholarship (21181008).

REFERENCES

1. World Health Organization (2020). Available online at: www.who.int (accessed July 27, 2020).

2. Berry DJ, Dyer A, Cai X, Gasrde DB, Ning H, Thomas A, et al. Lifetime risks of cardiovascular disease. N Engl J Med. (2012) 366:321–9. doi: 10.1056/NEJMoa121848

3. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. (2000) 101:207–13. doi: 10.1161/01.cir.101.2.207

4. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. (2005) 45:89–118. doi: 10.1146/annurev.pharmtox.45.120403.095748

5. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. (2004). 109:1139–43. doi: 10.1161/01.CIR.0000135157.20177-SA

6. Hall A. Rho GTPases and the actin cytoskeleton. Science. (1998) 279:509–14. doi: 10.1126/science.279.5350.509

7. Van Aelst L, D’Souza-Schorey C. Rho GT Pases and signaling networks. Genes Dev. (1997) 11:2295–322. doi: 10.1101/gad.11.18.2295

8. Riento K, Ridley AJ. ROCKs: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. (2003) 4:446–56. doi: 10.1038/nrm1128

9. Rikita Te, Kim HH, Huang Z, Seto M, Yano K, Asano T, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke. (2005) 36:2251–7. doi: 10.1161/01.STR.0000181077.84981.11

10. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Circ Res. (2005) 97:227–32. doi: 10.1161/01.STR.0000181077.84981.11

11. Takemoto M, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. (2011) 108:229–36. doi: 10.1161/CIRCRESAHA.116.308537

12. Cerda A, Fajardo CM, Basso RG, Hirata MH, Hirata RDC. Role of microRNAs in statin-induced nitric oxide release in human endothelial cells. Arq Bras Cardiol. (2010) 86:201–5. doi: 10.1590/S0066-78992010000100027

13. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. (1998) 273:24266–71. doi: 10.1074/jbc.273.37.24266

14. Wang L, Xu Z, Kitajima I, Wang Z. Effects of different statins on endothelial nitric oxide synthase and AKT phosphorylation in endothelial cells. Int J Cardiol. (2008) 127:33–9. doi: 10.1016/j.ijcard.2007.10.034

15. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. (2010) 11:597–610. doi: 10.1038/nrg2843

16. Albes J, Fehmann T, Fischer U, Backes C, Galata V, Minet M, et al. An estimate of the number of true human miRNAs. Nucleic Acids Res. (2019) 47:3353–64. doi: 10.1093/nar/gkx997

17. Pettea M, Salzburg XL. Between a chicken and a grape: estimating the number of human genes. Genome Biol. (2010) 11:206. doi: 10.1186/gb-2010-11-5-206

18. Kyrollos DG, Reid B, Dick K, Green JR. RPmirDIP: reciprocal perspective improves miRNA and targeting prediction. Sci Rep. (2020) 10:1–13. doi: 10.5065/D2L8JJK

19. Wang L, Iroh I, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. (2016) 231:25–30. doi: 10.1002/jcp.25056

20. Wong CM, Wei L, Au SLK, Fan DNY, Zhou Y, Tsang FHC, et al. MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. Oncotarget. (2015) 6:13658. doi: 10.18632/oncotarget.3700

21. Zhou L, Xu Z, Ren X, Chen K, Xin S. MicroRNA-124 (MiR-124) inhibits cell proliferation, metastasis and invasion in colorectal cancer by downregulating Rho-associated protein kinase 1 (ROCK1). Cell Physiol Biochem. (2016) 38:1785–95. doi: 10.1159/000443117

22. Zambrano T, Hirata RD, Hirata MH, Cerda Å, Salazar LA. Altered microRNA profiling in statin-induced HepG2 cells: a pilot study identifying potential new biomarkers involved in lipid-lowering treatment. Cardiovasc Drugs Ther. (2015) 29:509–18. doi: 10.1007/s10557-016-6272-0

23. Minami Y, Satoh M, Maesaawa C, Takahashi Y, Tabuchi T, Itoh T, et al. Effect of atorvastatin on microRNA 221/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease. Eur J Clin Invest. (2009) 39:359–67. doi: 10.1111/j.1365-2362.2009.02110.x

24. Mohammadzadeh N, Montecucco F, Carbone F, Xu S, Al-Rasadi K, Saehekb A. Statins: Epiprugs with effects on endothelial health? Eur J Clin Invest. (2020) 50:e13388. doi: 10.1111/euci.13388

25. Cerda A, Fajardo CM, Basso RG, Hirata MH, Hirata RDC. Role of microRNAs in statin-induced nitric oxide release in human endothelial cells. Arq Bras Cardiol. (2010) 104:195–201. doi: 10.5935/abc.2010.014912

26. Dunning MJ, Smith ML, Ritchie ME, Tavares, S. beadarray: R classes and methods for illumina bead-based data. Bioinformatics. (2007) 23:2183–4. doi: 10.1093/bioinformatics/btm311

27. Kauffmann A, Gentleman R, Huber W. arrayQualityMetrics-a bioconductor package for quality assessment of microarray data. Bioinformatics. (2009) 25:415–6. doi: 10.1093/bioinformatics/btn647

28. Smith ML, Baggerly KA, Bengtsson H, Ritchie ME, Hansen KD. illuminaio: an open source IDAT parsing tool for illumina microarrays. (2013). F1000Res. 2:264. doi: 10.12688/f1000research.2-264.v1

29. Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. (2015) 12:115–21. doi: 10.1038/nmeth.3252

30. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian microRNAs. Elife. (2015) 4:e05005. doi: 10.7554/eLife.05005

DI19-2018 and DI19-0094). KL is the recipient of ANID scholarship (21181008).
37. Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. *Nucleic Acids Res.* (2020) 48:D127–31. doi: 10.1093/nar/gkz757

38. Liang S, Su W, Zhou L, Cao Y, Zhou X, Liu S, et al. Statin downregulation of miR-652-3p protects endothelium from dyslipidemia by promoting iSL1 expression. *Metabolism.* (2020) 107:154226. doi: 10.1016/j.metabol.2020.154226

39. Zhang C. MicroRNAs: role in cardiovascular biology and disease. *Clin. Sci.* (2008) 114:699–706. doi: 10.1042/CS20070211

40. Ono K, Kuwabara Y, Han J. MicroRNAs and cardiovascular diseases. *FEBS J.* (2011) 278:1619–33. doi: 10.1111/j.1742-4658.2011.08090.x

41. Rajewsky N. microRNA target predictions in animals. *Nat. Genet.* (2006) 38:S8–S13. doi: 10.1038/ng1798

42. Oliveira AC, Bovolenta LA, Nachtigall PG, Lemke N, Herkenhoff ME. The use of distinct MicroRNA target prediction tools enhances the performance of analyses. *Front. Genet.* (2017) 8:59. doi: 10.3389/fgen.2017.00559

43. Fang Z, Rajewsky N. The impact of miRNA target sites in coding sequences and in 3’ UTRs. *PLoS ONE.* (2011) 6:e18067. doi: 10.1371/journal.pone.0018067

44. Selbach M, Schwahnhaesser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. *Nature.* (2008) 455:58–63. doi: 10.1038/nature07228

45. Garbern JC, Mummery CL, Lee RT. Model systems for cardiovascular regenerative biology. *Cold Spring Harb Perspect Med.* (2013) 3:a014019. doi: 10.1101/cshperspect.a014019

46. Medina-Leyte DJ, Domínguez-Pérez M, Mercado I, Villarreal-Molina MT, Jacobo-Albavera L. Use of human umbilical vein endothelial cells (HUVEC) as a model to study cardiovascular disease: a review. *Appl. Sci.* (2020) 10:938. doi: 10.3390/app10030938

47. Fukata Y, Kaibuchi K, Amano M. Rho–Rho kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. *Trends Pharmacol. Sci.* (2001) 22:32–9. doi: 10.1016/s0165-6147(00)01596-0

48. Liu H, Hou T, Ju W, Xing Y, Zhang X, Yang J. MicroRNA-122 downregulates Rho-associated protein kinase 2 expression and inhibits the proliferation of prostate carcinoma cells. *Mol Med Rep.* (2019) 19:3882–8. doi: 10.3892/mmr.2019.9995

49. Niu Y, Tang G. miR-185-5p targets ROCK2 and inhibits cell migration and invasion of hepatocellular carcinoma. *Oncol. Lett.* (2019) 17:9087–93. doi: 10.3892/ol.2019.10144

50. Miller-Delaney SE, Bryan K, Das S, McKiernan RC, Bray IM, Reynolds JP, et al. Differential DNA methylation profiles of coding and non-coding genes define hippocampal sclerosis in human temporal lobe epilepsy. *Brain.* (2015) 138:616–31. doi: 10.1093/brain/awu373

51. Hui L, Wu H, Yang N, Guo X, Jiang X. Identification of prognostic microRNA candidates for head and neck squamous cell carcinoma. *Oncol. Rep.* (2016) 35:3321–30. doi: 10.3892/or.2016.4698

52. Osip’Yants AI, Knyazev CE, Galatenko AV, Nyushko KM, Galate nko VV, Shkurnikov MY, et al. Changes in the level of circulating hsa-miR-297 and hsa-miR-19b-3p miRNAs are associated with generalization of prostate cancer. *Bull Exp Biol Med.* (2017) 162:379–82. doi: 10.1007/s10517-017-3620-6

53. Xu K, Liang X, Shen K, Cui D, Zheng Y, Xu J, et al. miR-297 modulates multidrug resistance in human colorectal cancer by down-regulating MRP-2. *Biochem. J.* (2012) 446:291–300. doi: 10.1042/BJ20120386

54. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. *Nature.* (1990) 343:425–30. doi: 10.1038/343425a0

55. Yang D, Knight RA, Han Y, Kariki K, Zhang J, Chopp M, et al. Statins protect the blood brain barrier acutely after experimental intracerebral hemorrhage. *J Behav Brain Sci.* (2013) 3:100. doi: 10.4236/jbbs.2013.31010

56. Yang D, Zhang J, Han Y, James E, Chopp M, Seyfried DM. Acute statin treatment improves recovery after experimental intracerebral hemorrhage. *World J. Neurosci.* (2013) 3:69. doi: 10.4236/wjns.2013.32010

57. Chen CJ, Ding D, Ironside N, Buei TJ, Elder LJ, Warren A, et al. Statins for neuroprotection in spontaneous intracerebral hemorrhage. *Neurology.* (2019) 93:1056–66. doi: 10.1212/WNL.0000000000008627

58. Sen-Banerjee S, Mir S, Lin Z, Hamik A, Atkins GB, Das H, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. *Circ. Hertogt.* (2005) 111:720–6. doi: 10.1161/CIRCULATIONAHA.105.141614

59. Watabe T, Nishihara A, Shimizu K, Yamashita C, Shimizu K, Miyazawa K, et al. TGF-β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell–derived endothelial cells. *J Cell. Biol.* (2003) 163:1303–11. doi: 10.1083/jcb.20030514

60. Giannotti G, Doerries C, Mocharla PS, Mueller MF, Bahlmann FH, Horvath T, et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. *Hypertension.* (2010) 55:1389–97. doi: 10.1161/hypertensionaha.109.141614

61. Govek EE, Newey SE, Van Aelst L. The role of the Rho GTPases in neuronal development. *Genes Dev.* (2005) 19:1–49. doi: 10.1101/gad.125460

62. Yamashita K, Kotani Y, Nakajima Y, Shimazawa M, Yoshimura S, Nakashima S, et al. Fusudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. *Brain Res.* (2007) 1154:215–24. doi: 10.1016/j.brainres.2007.04.013

63. Li Q, Huang XJ, He W, Ding J, Jia JT, Fu G, et al. Neuroprotective potential of fusudil mesylate in brain ischemia-reperfusion injury of rats. *Cell Mol Neurobiol.* (2009) 29:169–80. doi: 10.1007/s10571-008-9308-8

64. Van der Heijden M, Versteilen AM, Spikema P, van Nieuw Amerongen GP, Musters RJ, Groeneveld AJ. Rho-kinase-dependent F-actin rearrangement is involved in the inhibition of PI3-kinase/Akt during ischaemia-reperfusion-induced endothelial cell apoptosis. *Apopotics.* (2008) 13:404–12. doi: 10.1095/biolopen.107.071734

65. Torella D, Iaconetti C, Catalucci D, Ellison GM, Leone A, Waring CD, et al. MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. *Circ. Res.* (2011) 109:880–93. doi: 10.1161/CIRCRESAHA.111.240150

66. Mohajeri M, Banach M, Atkin SL, Butler AE, Ruscica M, Watts GF, et al. MicroRNAs: novel molecular targets and response modulators of statin therapy. *Trends Pharmacol Sci.* (2018) 39:967–81. doi: 10.1016/j.tips.2018.09

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Leal, Saavedra, Rebolloso and Salazar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction which permits which cannot comply with these terms.